Expert Interview
A Second Look: Discussing Ipsen's Phase 3 data from the ELMWOOD study of elafibranor in patients with primary sclerosing cholangitis (PSC).
Ticker(s): IPSEY, IPN.XPARInstitution: Yale University
- Academic hepatologist, Associate Professor of Medicine (Digestive Diseases) and Director, Yale Viral Hepatitis Program.
- Treats patients with chronic liver diseases including the entire spectrum from cirrhosis, liver failure, and post-transplant; Approximately 5-10% of his patients have chronic pruritus symptoms, 200 patients with biopsy-proven NASH and a larger cohort of NAFLD, and 70 patients with PBC/PSC.
- Has served on the national steering committees for large observational cohort studies for liver disease and has published over 100 papers in the area of GI and liver diseases.
How frequently do you manage or consult on cases of primary sclerosing cholangitis (PSC) in your clinical practice?
Added By: sara_adminCan you discuss elafibranor’s mechanism of action and its potential therapeutic role in cholestatic liver diseases like PSC?
Added By: sara_adminBased on the available data, how would you compare elafibranor’s efficacy and safety profile to other investigational therapies or off-label treatments currently used for PSC?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
